Gossamer Bio, Inc. (NASDAQ:GOSS) has been assigned a consensus recommendation of “Buy” from the six brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $22.80.
A number of research firms have commented on GOSS. Zacks Investment Research cut shares of Gossamer Bio from a “buy” rating to a “hold” rating in a research note on Tuesday, January 12th. HC Wainwright restated a “buy” rating and set a $24.00 target price (up previously from $15.00) on shares of Gossamer Bio in a research note on Thursday, December 17th.
NASDAQ GOSS traded down $0.85 on Tuesday, reaching $10.09. 1,206,427 shares of the stock were exchanged, compared to its average volume of 631,664. Gossamer Bio has a one year low of $7.52 and a one year high of $16.79. The firm has a market capitalization of $766.11 million, a PE ratio of -3.07 and a beta of 1.34. The company’s 50-day simple moving average is $10.44 and its two-hundred day simple moving average is $10.92. The company has a current ratio of 17.36, a quick ratio of 17.36 and a debt-to-equity ratio of 0.46.
About Gossamer Bio
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial in patients with chronic spontaneous urticarial.
See Also: How Do Mutual Funds Work?
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.